A Blood Test for Cancer Moves Closer to FDA Review, and a CDC Warning on Injectable Glutathione

A routine blood draw is at the center of two important health updates today. The FDA has released briefing materials ahead of its review of GRAIL’s Galleri, a blood-based multi-cancer screening test proposed for adults 50 and older. The test looks for cancer-related DNA patterns in blood, but it is not a diagnosis and has not replaced standard screening. (FDA briefing package)

The FDA briefing reports cancer detection rates of 0.49% in PATHFINDER 2-106 detections among 21,418 participants, and 0.51% in NHS-Galleri, involving 259 of 50,739 participants. The document also describes more cancers being detected when Galleri was added to guideline-recommended screening. Still, the FDA says a negative result does not rule out cancer, and people should continue mammograms, colorectal screening, lung screening, and other recommended tests.

Separately, the CDC and FDA report illnesses after injectable glutathione compounded with dietary-supplement-grade ingredients. The FDA says at least 30 patients experienced adverse events, including fever, chills, pain, dizziness, and sepsis-like symptoms. Elevated bacterial endotoxins are a suspected cause. Dietary-supplement-grade ingredients should not be used for sterile injections.

There is also a broader oversight concern: analyses by MedicalDaily and MedicalXpress found nearly 600 delayed FDA postmarket studies involving almost 350 products. A delay alone does not prove a medicine is unsafe, but it can leave patients and clinicians waiting for important safety or effectiveness evidence.

For now, keep recommended screenings current, ask questions before any compounded injection, and seek urgent care for severe symptoms after an IV treatment. Would clearer public reporting on test performance, injection ingredients, and delayed studies help your household make safer health decisions?